A randomized phase 2 trial of erlotinib versus pemetrexed as second-line therapy in the treatment of patients with advanced EGFR wild-type and EGFR FISH-positive lung adenocarcinoma.

@article{Li2014ARP,
  title={A randomized phase 2 trial of erlotinib versus pemetrexed as second-line therapy in the treatment of patients with advanced EGFR wild-type and EGFR FISH-positive lung adenocarcinoma.},
  author={Ning Li and Wei Ou and Hua Yang and Qian-wen Liu and Song-liang Zhang and Bao-Xiao Wang and Si-Yu Wang},
  journal={Cancer},
  year={2014},
  volume={120 9},
  pages={1379-86}
}
BACKGROUND The current study was undertaken to investigate the efficacy and safety of erlotinib versus pemetrexed as second-line therapy for patients with advanced epidermal growth factor receptor (EGFR) wild-type and EGFR fluorescence in situ hybridization (FISH)-positive lung adenocarcinoma. METHODS In this open-label, randomized, phase 2 study, patients with EGFR wild-type and EGFR FISH-positive adenocarcinoma who had developed disease progression after 1 prior platinum-based chemotherapy… CONTINUE READING
10 Citations
26 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 10 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 26 references

A phase II trial comparing pemetrexed with gefitinib as the second-line treatment of nonsquamous NSCLC patients with wild-type EGFR (CTONG0806) [abstract

  • JJ Yang, Y Cheng, MF Zhao
  • J Clin Oncol
  • 2013
1 Excerpt

Similar Papers

Loading similar papers…